Tianjin Ringpu Bio-Technology Co.,Ltd.
XSEC:300119 Stock Report
Tianjin Ringpu Bio-TechnologyLtd Balance Sheet Health
Financial Health criteria checks 5/6 Tianjin Ringpu Bio-TechnologyLtd has a total shareholder equity of CN¥5.0B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 25.7%. Its total assets and total liabilities are CN¥7.4B and CN¥2.5B respectively. Tianjin Ringpu Bio-TechnologyLtd's EBIT is CN¥361.4M making its interest coverage ratio 12.3. It has cash and short-term investments of CN¥1.7B.
Key information
25.7%
Debt to equity ratio
Interest coverage ratio 12.3x Cash CN¥1.69b Equity CN¥4.96b Total liabilities CN¥2.48b Total assets CN¥7.44b
Recent financial health updates
Show all updates
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) announces an Equity Buyback for CNY 160 million worth of its shares. Nov 07
Investor sentiment improves as stock rises 19% Nov 06
Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.21 in 3Q 2023) Oct 30
Investor sentiment deteriorates as stock falls 16% Oct 15
Tianjin Ringpu Bio-Technology Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Sep 30
Investor sentiment improves as stock rises 18% Sep 27
Second quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.21 in 2Q 2023) Aug 24
Now 20% overvalued Jul 19
Tianjin Ringpu Bio-Technology Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024 Jun 29
First quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 1Q 2023) Apr 26
Full year 2023 earnings released: EPS: CN¥0.98 (vs CN¥0.75 in FY 2022) Mar 31 Tianjin Ringpu Bio-Technology Co.,Ltd., Annual General Meeting, Apr 19, 2024
Now 23% overvalued Mar 11
Investor sentiment improves as stock rises 16% Feb 08
Now 33% overvalued Feb 06
Tianjin Ringpu Bio-Technology Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024 Dec 30
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) announces an Equity Buyback for CNY 80 million worth of its shares. Oct 29
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) announces an Equity Buyback for CNY 80 million worth of its shares. Oct 28
Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 3Q 2022) Oct 26
Tianjin Ringpu Bio-Technology Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
Second quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.15 in 2Q 2022) Aug 26
Tianjin Ringpu Bio-Technology Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 08 June 2023 Jun 03
First quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.16 in 1Q 2022) Apr 28
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2021) Oct 27
Tianjin Ringpu Bio-Technology Co.,Ltd. Announces Executive Appointments Sep 15
Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.22 in 2Q 2021) Aug 26
Tianjin Ringpu Bio-Technology Co.,Ltd. Announces Cash Dividend of A Shares for 2021, Payable on 13 June 2022 Jun 08
First quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.29 in 1Q 2021) May 02
No independent directors Apr 27
Tianjin Ringpu Bio-Technology Co.,Ltd. Approves Cash Dividend for the Year 2021 Apr 20
Tianjin Ringpu Bio-Technology Co.,Ltd., Annual General Meeting, Apr 18, 2022 Mar 31
Tianjin Ringpu Bio-Technology Co.,Ltd., Annual General Meeting, Apr 18, 2022 Mar 30
Tianjin Ringpu Bio-Technology Co.,Ltd. Proposes Dividend for Year 2021 Mar 29
Full year 2021 earnings released: EPS: CN¥1.03 (vs CN¥1.01 in FY 2020) Mar 29
Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.26 in 3Q 2020) Oct 28
Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.19 in 2Q 2020) Aug 28
Investor sentiment deteriorated over the past week Jun 14
First quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.18 in 1Q 2020) Apr 30
Investor sentiment improved over the past week Mar 23 Tianjin Ringpu Bio-Technology Co., Ltd. Proposes Cash Dividend for the Year 2020
Tianjin Ringpu Bio-Technology Co., Ltd. announced that it expects to receive CNY 1.336 billion in funding Mar 16
Revenue misses expectations Mar 05
Full year 2020 earnings released: EPS CN¥1.01 (vs CN¥0.49 in FY 2019) Mar 04
New 90-day high: CN¥26.39 Feb 20
Investor sentiment improved over the past week Jan 28
New 90-day high: CN¥23.90 Jan 27
Tianjin Ringpu Bio-Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021 Jan 22
New 90-day low: CN¥18.23 Jan 11
New 90-day low: CN¥19.34 Dec 23
Third quarter earnings released Oct 29
Market bids up stock over the past week Oct 13
Earnings released Aug 27
Financial Position Analysis
Short Term Liabilities: 300119's short term assets (CN¥3.3B) exceed its short term liabilities (CN¥1.7B).
Long Term Liabilities: 300119's short term assets (CN¥3.3B) exceed its long term liabilities (CN¥736.6M).
Debt to Equity History and Analysis
Debt Level: 300119 has more cash than its total debt.
Reducing Debt: 300119's debt to equity ratio has increased from 21% to 25.7% over the past 5 years.
Debt Coverage: 300119's debt is well covered by operating cash flow (42.2%).
Interest Coverage: 300119's interest payments on its debt are well covered by EBIT (12.3x coverage).
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}